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Abstract
The Zscan4 family of genes, encoding SCAN-domain and zinc finger-containing proteins, has been implicated in the control
of early mammalian embryogenesis as well as the regulation of pluripotency and maintenance of genome integrity in
mouse embryonic stem cells. However, many features of this enigmatic family of genes are poorly understood. Here we
show that undifferentiated mouse embryonic stem cell (ESC) lines simultaneously express multiple members of the Zscan4
gene family, with Zscan4c, Zscan4f and Zscan4-ps2 consistently being the most abundant. Despite this, between only 0.1
and 0.7% of undifferentiated mouse pluripotent stem cells express Zscan4 protein at a given time, consistent with a very
restricted pattern of Zscan4 transcripts reported previously. Herein we demonstrate that Zscan4 expression is regulated by
the p110a catalytic isoform of phosphoinositide 3-kinases and is induced following exposure to a sub-class of DNA-damage-
inducing agents, including Zeocin and Cisplatin. Furthermore, we observe that Zscan4 protein expression peaks during the
G2 phase of the cell cycle, suggesting that it may play a critical role at this checkpoint. Studies with GAL4-fusion proteins
suggest a role for Zscan4 in transcriptional regulation, further supported by the fact that protein interaction analyses
demonstrate that Zscan4 interacts with both LSD1 and CtBP2 in ESC nuclei. This study advances and extends our
understanding of Zscan4 expression, regulation and mechanism of action. Based on our data we propose that Zscan4 may
regulate gene transcription in mouse ES cells through interaction with LSD1 and CtBP2.
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Introduction
Embryonic stem cells (ESCs) self-renew and are pluripotent,
meaning they can differentiate into all cells comprising an adult
organism [1]. These properties have made ESCs an attractive
source of differentiated cell types for use in both drug discovery
and regenerative medicine. While the potential of ESCs has been
widely recognized, it is imperative that the mechanisms regulating
their self-renewal, pluripotency and stability are better understood,
to ensure their efficacy and safety.
The extrinsic factors, signaling pathways and transcription
factor networks that contribute to maintenance of mouse ESC self-
renewal and pluripotency, referred to as the ‘ESC state’, have been
extensively studied [1,2,3,4]. Leukaemia inhibitory factor (LIF)
and Bone morphogenetic protein 4 (BMP4) are the key cytokines
required for maintenance of ESC self-renewal in culture, acting
via the Jak-Stat3 and Smad-Id pathways respectively [5,6,7].
Inhibition of glycogen synthase kinase 3 (Gsk-3), which mimics
both activation of the Wnt pathway and growth factor-induced
PI3K signaling, can enhance mouse ESC self-renewal [8,9] and
assist in maintaining the ‘ground state’ of mouse ESC pluripotency
[10,11,12]. Inhibition of MAPK signaling, in addition to Gsk-3
inhibition (referred to as 2i conditions) is sufficient to maintain self-
renewal of mouse ESCs in the absence of additional exogenous
factors [10]. Phosphoinoside 3-kinase (PI3K) signaling has also
been implicated in the maintenance of both mouse [13,14,15] and
human ESC [16] pluripotency.
Oct4, Sox2 and Nanog are amongst the most important
transcription factors that contribute to regulation of ESC
pluripotency, often referred to as the ‘core transcription factors’
or ‘master regulators’ [1,17]. Other transcription factors work in
concert with these core factors and include Zfx [18], Klf 2 & 4
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[19], c-Myc [20], Esrrb [21] and Tbx3 [13,21]. In addition,
epigenetic regulation has been proposed to play an important role
in control of the ESC state [1,22,23].
Recently, members of the Zscan4 family of zinc finger proteins
have been identified as important contributors to the maintenance
of the pluripotent state of mouse ESCs [24,25]. The Zscan4 family
comprises 9 very closely related gene paralogues located on mouse
chromosome 7 [24,26]. Full-length Zscan4 proteins comprise an
N-terminal SCAN domain of approximately 160 residues and 4
zinc finger motifs, located towards the C-terminus [24,26]. SCAN
domains can mediate dimerisation of other Zinc finger-containing
proteins [27,28,29], although to date this has not been demon-
strated for the Zscan4 family.
In terms of the functional role of Zscan4 family members, Falco
et al., first identified Zscan4d as a gene upregulated during zygotic
genome activation in mouse 2-cell stage embryos [26]. Blockade of
Zscan4d expression during pre-implantation development led to a
delay in 2-cell to 4-cell progression and blastocysts that did develop
were unable to implant or proliferate in culture [26]. Interestingly,
in mouse ESCs Zscan4 mRNA exhibits a very unusual pattern of
expression, restricted to only a small proportion of cells [26,30].
Studies have suggested that Zfp206 and Smad4 play positive and
negative roles respectively in regulating Zscan4 expression [31,32].
We first identified Zscan4c as a gene whose expression is down-
regulated in mouse ESCs following inhibition of PI3K signaling
[24] and demonstrated that knock-down of Zscan4 family
members decreased self-renewal of mESCs, consistent with a role
for Zscan4 proteins in maintenance of the ESC state [24]. More
recently it has been reported that Zscan4 plays a key role in
maintaining the stability and integrity of the ESC genome [25].
Furthermore its transient expression can enhance both the
efficiency of generation of induced pluripotent stem cells [33]
and genome stability during the reprogramming phase [34]. More
recently, Zscan4 has also been shown to be capable of restoring
developmental pluripotency to embryonic stem cells [35]. These
findings suggest that the Zscan4 family plays multiple roles in
maintenance of the ESC state.
To increase our understanding of the biology of the Zscan4
family of proteins we have investigated the patterns and regulation
of expression of Zscan4 genes and proteins in mouse ESCs and
probed the mechanisms of action of Zscan4. Here we report that
multiple Zscan4 genes are expressed in different ESC lines,
including genes previously proposed as pseudogenes. In multiple
pluripotent mouse stem cell lines Zscan4 protein expression was
consistently found to be highly restricted, with between 0.1 and
0.7% Zscan4-positive cells detected. We also show that Zscan4
protein levels are modulated by PI3K and Gsk-3-dependent
signaling, in response to DNA damage and during the G2 phase of
the cell cycle. Consistent with a role as a potential regulator of
transcription, we demonstrate that Zscan4c modulates transcrip-
tion in a heterologous system and that Zscan4 proteins are located
in the nucleus, where they interact with components of co-
repressor complexes, including LSD1 and CtBP2. Based on our
current understanding of Zscan4 biology we believe that this gene
family represents an intriguing new paradigm for the control of the
ESC state.
Materials and Methods
Culture of mouse pluripotent cells
The mouse ES cell lines E14tg2a [36], E14 Gsk-3 double knock-
out (DKO; [37]), CCE, CGR8, IOUD2, R1 and ZE3-MC-1 [25]
and the mouse iPS cell line [38] were cultured as described
previously [8,14,39].
Generation of GFP-Zscan4c and Zscan4c-V5-His mouse
ES cell lines
An eGFP-Zscan4c fusion protein was generated by amplifying
the Zscan4c coding sequence with the primers: forward (59-T-
TATGGCTTCACAGCAGGCA) and reverse (59- TTAATTG-
CGGCCGCTCAGTCAGATCTGTGGTAAT). The resulting
product was cloned into SmaI/NotI digested pTRE-Tight
(Clontech) which contained the coding sequence for eGFP. This
generated an in-frame N-terminal fusion between eGFP and
Zscan4c. To generate ESCs with eGFP-Zscan4c under the control
of Tet-on regulation, R1 mESCs containing the Tet-On Advanced
Transactivator (Clontech; a kind gift of Giusi Manfredi, University
of Bath) were co-transfected by electroporation with pTRE-eGFP-
Zscan4c and a vector conferring resistance to Hygromycin B.
Clones were selected in 300 mg/ml Hygromycin B, expanded,
screened for expression and further characterised (Supplemental
Figure S1). The karyotype of clones used for further analyses was
checked and confirmed as normal (data not shown). To generate
ESCs expressing an inducible c-terminal V5-His epitope tagged
version of Zscan4c under the regulation of the Tet-off system,
Zscan4c-V5-His was PCR amplified from a pcDNA3.1vector
containing the required insert [24] using the primers forward (59-
AATGTCGACTAATACGACTCACTATAGGG) and reverse
(59-AATGTCGACTAGAAGGCACAGTCGAGG). This prod-
uct was blunt-end ligated into the Tet-off response plasmid
pUHD10-3 [40] to create the vector pTet-off-Zscan4c-His-V5. To
generate inducible Zscan4c-Tet-off ESC lines, linearized pTet-off-
Zscan4c-His-V5 was electroporated as previously described [14]
into E14tg2A (clone R63) ESCs which constitutively express the
tetracycline transactivator (tTA) driven by the CAG promoter
[41]. Transfectants were selected in G418 and surviving clones
expanded and screened by immunoblotting for the induction of
Zscan4c expression after withdrawal of tetracycline. Clones with
the highest degree of inducible expression were used in this study
and further characterised (Supplemental Figure S2). Clones were
routinely cultured in the presence of 1 mg/ml tetracycline to
maintain transgene expression switched off, tetracycline was
removed to induce Zscan4c-V5-His expression.
Generation of mouse ES cell lines expressing
myristyolated p110a
A version of p110a containing an in-fame N-terminal N-
myristoyl transferase recognition peptide sequence,
MGSSKSKPK, was amplified by PCR from the plasmid
pPyCAG-myrp110a-IP [42] and subcloned into the piggyBac
vector pPBCAGcHAIN to generate pPB-myr-p110a. One day
prior to transfection, 26104 OCRG9 mouse ESCs (Rex1-GFP/
Oct3/4-CFP double knock-in ES cells)/well were plated into 12-
well cell culture trays. The following day, 1 mg of pPB-myr-p110a
and 1 mg transposase expressing helper plasmid (pCAG-PBase)
were mixed in 25 ml of GMEM without serum. 25 ml of diluted
Lipofectamine2000 (2 ml Lipofectamine2000 plus 23 ml GMEM)
was added to the DNA mix and incubated at room temperature
for 10 min. 450 ml of GMEM plus serum was then added and the
mixture applied to prepared cells. After 3 hours, the medium was
replaced with fresh medium. Selection with G418 was initiated
after a further 24 h and colonies generated after 6 days in selection
were picked and expanded.
RNA isolation and RT-PCR
RNA was isolated and RT-PCR performed as previously
described [43]. The list of primers used in this study are
summarised in Table S1.
Regulation of Expression and Mode of Action of Zscan4
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Cloning and sequencing of Zscan4 transcripts
RNA was isolated and RT-PCR performed as above using the
following primers (Forward 59-ACAATGGCTTCACAGCAGG,
Reverse 59-ACGATGGTAAGTGGATGATTGG) and limited
amplification (22 cycles). PCR products were TOPO cloned into
pcDNA3.1 (Invitrogen). Clones were picked, plasmid DNA
extracted and 96 insert verified clones were sequenced using the
primer 59-CATCCTAGAACATTCTTCACAC. All primers used
bind to all 9 Zscan4 paralogs with equal efficiency. Sequences
were analysed using Sequencher (GeneCodes).
Generation of transcriptional reporters
A synthetic GAL4-UAS promoter, containing five GAL4
bindings sites (59-CGGAGTACTGTCCTCCG-39), was cloned
into the pGL4.26 luciferase reporter (Promega), using the synthetic
sequences: forward 59- CCGGAGTACTGTCCTCCGTACGG-
AGTACTGTCCTCCGTATGCCGGAGTACTGTCCTCCGA-
TCGGAGTACTGTCCTCCGTATGCCGGAGTACTGTCCT-
CCGC & reverse 59-TCGAGCGGAGGACAGTACTCCGG-
CATACGGAGGACAGTACTCCGATCGGAGGACAGTACT-
CCGGCATACGGAGGACAGTACTCCGTACGGAGGACAG-
TACTCCGGGTAC, as shown in Supplemental Figure S3. The
trans-activator reporter plasmid, pFA-CMV (Stratagene), was used
to create a series of Zscan4c-Gal4 fusion proteins using the primer
sequences listed in Supplemental Table S2. A Nanog Gal4-fusion
was also generated. After sequence verification of the constructs,
transcriptional activity was tested in heterologous Hek293 cells.
For transfection, cells were plated at 60,000 cells/well in a 96-well
dish and incubated for 24 h in 100 ml DMEM plus 10% (v/v)
FBS, which was subsequently replaced with 50 ml of the same
medium. Following this, 100 ng pGL4.26 GAL4-UAS, 20 ng
pFA-CMV SCAN (or SCAN+ or SCAN+ZnF) and 20 ng phRL-
TK (Renilla plasmid to control for transfection efficiency) were
combined in 12.5 ml Optimem and incubated at room tempera-
ture for 5 min. The DNA was then combined with diluted
Lipofectamine 2000 (0.5 ml in 12.5 ml Opti-Mem) and incubated
for 20 min before addition to cells. After 24 h luciferase detection
was carried out using Dual-Glo Luciferase Assay System (Promega
– E2920). After subtraction of background fluorescence for Renilla
and Firefly luciferase, the ratio of reporter (firefly) luminescence to
control (Renilla) luminescence was calculated and values were
normalized relative to Gal DBD response alone – this value
represents the Relative Response Ratio.
Generation of mouse pan-Zscan4 antibodies
Polyclonal rabbit antisera were generated against a Zscan4-
specific peptide (GVPQDSTRASQGTSTC, amino acids 322–
337; anti-pan Zscan4) by Millipore/Merck according to company
procedures. Specificity for Zscan4 was confirmed by immunoblot-
ting in the presence and absence of blocking peptide and
immunoprecipitation (Figure S4).
Immunofluorescence and flow cytometry
Cells were fixed with 4% (w/v) paraformaldehyde for 20 min,
permeablised in 1% Triton X-100 for 20 min, blocked for 1 h in
1% blocking reagent (Roche), washed and incubated with 1:500
dilution of anti-Zscan4 antisera. After washing, a 1:100 dilution of
anti-rabbit-Texas Red antibody (Vector Laboratories) was added.
After a second round of washing DAPI was added for 20 min.
Samples were again washed and mounted under a coverslip with
fluorescence mounting medium (DAKO). Fluorescence was
visualised using Leica DMI 4000B fluorescence microscope or
Zeiss LSM Meta Confocal Microscope (Bioimaging Suite,
University of Bath, UK). For cell cycle analyses by flow cytometry,
cells were trypsinised and fixed with 70% (v/v) ice-cold ethanol.
After washing with PBS and re-hydration for 10 min, cells were
incubated with 7-AAD (0.5 mg/ml) for 1.5 h at 4uC. A minimum
of 10,000 cell events were acquired using FACS Canto flow
cytometer (Becton-Dickinson) and analysed using FACS Diva
software. Alternatively, live cells were stained with Nuclear-ID
Red according to the manufacturer’s instructions (Enzo Life
Sciences) and a minimum of 140,000 cell events were analysed as
above.
Protein extraction, immunoprecipitation and
immunoblotting
Cytosolic or nuclear cell extracts were prepared as described
previously [44] and protein concentrations determined. To
generate total cell extracts RIPA lysis buffer (150 mM NaCl,
50 mM TrisHCl pH8, 1% (v/v) NP40, 0.5%(w/v) Na Deoxyco-
late, 0.1% (w/v) SDS, 25 U/ml Benzonase, 1 mM sodium
vanadate, 1 mM sodium molybdate, 10 mM sodium fluoride,
40 mg/ml PMSF, 0.7 mg/ml Pepstatin , 10 mg/ml Aprotinin,
10 mg/ml Leupeptin, 10 mg/ml Soyabean trypsin inhibitor) was
used. For immunoprecipitation, equal amounts of protein
(cytosolic or nuclear extracts) were pre-cleared with protein A
sepharose beads and then precipitated with either Nanotrap beads
(30 ml of 50% (v/v) slurry, Chromatek), pre-immune serum
(5 ml), anti-panZscan4 antiserum (5 ml), anti-LSD-1 (2 mg per
sample, Abcam, ab37165), anti-CtBP2 (2 mg per sample, BD
Transduction Labs, Cat No. 612044) or anti-V5 epitope (2 mg per
sample, Abcam ab27671) antibodies and immune complexes
captured on protein A or G sepharose beads, prior to extensive
washing with nuclear extraction buffer and boiling in Laemmli
buffer. For immunoblotting, 20 mg of each protein sample or the
entire immunoprecipitate was separated by SDS-PAGE and
transferred to nitrocellulose as previously described [45]. Immu-
noblotting was carried out with the following primary rabbit
polyclonal antibodies: 1:4000 anti-panZscan4 (Merck Millipore,
AB4340); 1:2000 LSD-1 (Abcam, ab37165); 1:5000 GFP (MBL,
598), or mouse monoclonal antibodies at 1:2000 anti-CtBP2 (BD
Transduction Laboratories, 612044), 1:5000 anti-V5 epitope
(Abcam, ab27671), 1:1000 c-H2AX (Merck Millipore clone
JBW301) or 1:20000 anti-GAPDH (Ambion, AM4300). Anti-
mouse or anti-rabbit secondary antibodies conjugated to horse-
radish peroxidase (DAKO) were used for detection and blots were
developed using ECL Prime according to the manufacturer’s
instructions (GE Healthcare). Protein relative quantification was
carried out using ImageQuant RT-ECL imager and analysed
using ImageQuant TL software (GE Healthcare). Blots were
stripped and reprobed as previously described [45].
Affinity purification of Zscan4 interacting proteins
GFP-Trap-A beads (Chromotek) provide a means of high
affinity purification in a single step, facilitating rapid precipitation
and the potential to capture less stable interactions. Following
induction of eGFP-Zscan4 expression by addition of Dox to GFP-
Zscan4c ESCs for 24 h, cells were harvested, washed in PBS and
cell pellets resuspended in cytosolic extraction buffer (20 mM
HEPES, 10 nM KCl, 1 mM EDTA, 10% (v/v) Glycerol, 1 mM
PMSF, 1 mg/ml Aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin,
5 mg/ml antipain, 157 mg/ml benzamidine, 5 mM b-glycerophos-
phate, 5 mM sodium fluoride, 1 mM sodium orthovanadate,
pH 7.9). After a 30 min incubation at 4uC, the suspension was
drawn through a 27G needle ten times and centrifuged at
1630006 g for 5 min at 4uC. The supernatant was removed and
designated ‘cytosol’. The remaining nuclear pellets were washed
Regulation of Expression and Mode of Action of Zscan4
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twice with ice cold cytosolic extraction buffer before being
resuspended in nuclear extraction buffer (20 mM HEPES,
10 nM KCl, 400 mM NaCl, 1 mM EDTA, 20% (v/v) Glycerol,
1 mM PMSF, 1 mg/ml Aprotinin, 1 mg/ml leupeptin, 1 mg/ml
pepstatin, 5 mg/ml antipain, 157 mg/ml benzamidine, 5 mM b-
glycerophosphate, 5 mM sodium fluoride, 1 mM sodium ortho-
vanadate, pH 7.9). Following rotation at 4uC for 1 h samples were
centrifuged at 1630006 g for 15 min. The supernatant was
collected and designated as the nuclear extract. Cytosolic and
nuclear fractions were cleared by centrifugation at 60,0006 g for
30 minutes at 4uC. A subsequent buffer exchange to immunopre-
cipitation (IP) buffer (50 mM Na2HPO4, 150 mM NaCl, pH 7.4)
was performed using Amicon centrifugal filters with a 10 kDa cut-
off according to the manufacturer’s protocol. Prior to immuno-
precipitation, lysates were pre-cleared with hydrated sepharose
beads for 1 h at 4uC on a rolling shaker. IPs were performed with
500 ml GFP-Trap-A beads (Chromotek) for 1–3 hours on a rolling
shaker at 4uC, followed by three washes with IP buffer. Bound
protein was eluted with 200 mM glycine at pH 2.5 and 1 M Tris-
base (pH 10.4) was added for neutralization. The eluates were
centrifuged at 1000 rpm for 1 minute and the supernatant
transferred to Amicon centrifugal filters with a 3 kDa cut-off for
concentration, according to the manufacturer’s recommendations.
SDS loading buffer was added and samples were boiled for
5 minutes. Proteins purified from uninduced and induced-derived
cell extracts were separated by large format SDS-PAGE, stained
with Coomassie blue and proteins enriched in the samples
prepared from induced cells were excised from the gel and
submitted for protein sequencing at The University of Bristol
Proteomics Facility (http://www.bristol.ac.uk/biochemistry/
proteomics/services.html). Automated in-gel tryptic digestion
was performed using a ProGest unit and resulting peptides
analysed by reverse-phase LC MSMS using an LTA-Orbitrap
Velos mass spectrometer. The mass spectral data from each
fraction was combined prior to database searching using Mascot to
identify the proteins present in the sample. Protein scores greater
than 64 were classed as significant (p,0.05). In addition, MSMS
analyses generated sequence data for a number of peptides.
Following these analyses and comparison to the mouse protein
sequence database, sequences were returned for 3 out of 4
proteins.
Results
Members of the Zscan4 family of genes have been implicated in
the regulation of pluripotency and genome stability, both functions
that impact on maintenance of the stem cell state of mouse ESCs
[24,25]. Two enigmatic features of the Zscan4 family are the
existence of 9 highly related gene paralogues and a very restricted
pattern of expression. These features suggest Zscan4 family
members may regulate the ESC state by novel mechanisms. Our
aim was to investigate the underlying basis of the restricted
expression pattern observed and further examine the mechanism
of action of Zscan4 in ESCs.
Multiple Zscan4 gene transcripts are expressed in self-
renewing mouse ESCs
Individual Zscan4 genes have been reported to be differentially
expressed in 2-cell stage mouse embryos and mouse ESCs, with
three members, Zscan4-ps1, Zscan4-ps2 and Zscan4-ps3, pro-
posed as pseudogenes [26]. In contrast, we have previously
detected Zscan4-ps2 transcripts in undifferentiated E14 ESCs
[24]. Given this discrepancy, and the importance of knowing
which Zscan4 genes are most highly expressed in ESC, thereby
ensuring that the most relevant are studied further, we investigated
the patterns of expression of individual Zscan4 genes in two
distinct mouse ESC lines. The very high sequence homology of
Zscan4 paralogues precluded a PCR-based approach to quantify
expression of individual genes and instead ESC cDNA was
subjected to a limited number of amplification cycles, using
primers that hybridise equally to transcripts from all 9 Zscan4
genes, prior to direct cloning into TOPO vectors. 96 clones were
selected at random for DNA sequencing and each individual
sequence returned was assigned to one of the 9 Zscan4 genes
based on information in the most recent build of the mouse
genome on NCBI (NCBIm37), as described in Supplemental
Figure S5. Figure 1A shows the relative expression of each Zscan4
transcript in E14 and CCE ESCs, compared to the 129.3 ESC line
reported previously [26]. Zscan4c, 4f and ps2 were the most
abundant transcripts detected in E14 and CCE ESCs. The most
striking difference observed was in the expression of Zscan4-ps2 in
both E14 and CCE, compared to its absence in 129.3.
Interestingly, phylogenetic analyses of the 9 Zscan4 paralogues
(Figure 1B), suggests that Zscan4c, 4f and ps2 are the most closely
related family members. In view of this, it is interesting that these 3
genes should consistently be the most abundant transcripts
detected, suggesting they constitute the most functionally relevant
Zscan4 genes in ESCs. We also detected expression of Zscan4-ps1
and Zscan4-ps3, suggesting their designation as pseudogenes,
based on lack of expression, is no longer correct in the light of this
new analysis.
Restricted patterns of Zscan4 expression are a feature of
multiple pluripotent mouse stem cell lines
To date, whole mount in situ hybridization of ESC colonies [26]
and Zscan4c-based promoter-reporter systems [25] have suggested
that expression of Zscan4 transcripts is restricted to between 3 and
5% of cells in a population of undifferentiated mouse ESCs at any
one time. We wanted to investigate this highly unusual pattern of
expression further and, in particular, determine whether Zscan4
protein shows a similarly restricted pattern of expression to Zscan4
RNAs. To achieve this aim we generated a pan-Zscan4 anti-
peptide polyclonal antibody, which detects Zscan4 in immunoblots
and is specifically blocked by the immunizing peptide (Supple-
mental Figure S4A). We initially used ZE3-MC1 ESCs, that
express Emerald-GFP under the control of a 2.6 kb fragment of
the Zscan4c promoter [25], to measure the correlation between
Zscan4 transcriptional reporter and protein expression. As shown
in Figure 2A (i) a robust correlation between detection of Emerald-
GFP and staining with the Zscan4 antibody was observed, with
Zscan4 protein being localized primarily in the nucleus
(Figure 2A(ii)). Having established concordance between the
Zscan4 reporter and protein expression, we analysed the
proportion of Zscan4 positive cells present in populations of
undifferentiated mouse ESC lines and a mouse iPSC line. Our
data, shown in Figure 2B, demonstrate that the proportion of cells
staining positive for Zscan4 protein is between 0.1 and 0.7%
(average of 0.33%) lower than the estimated number of cells
expressing Zscan4 transcripts reported previously [25,26]. Even
with the ZE3-MC1 reporter cell line generated and used by
Zalzman and colleagues [25], we consistently detected 10-fold
fewer Zscan4 positive cells than reported previously and we
obtained similar results when the expression was measured using
flow cytometry (average of 0.43% positive cells, S.E.M 0.03, n= 3,
events = 140,000–478,000). Despite these differences, our studies
clearly demonstrate that Zscan4 protein expression, like Zscan4
transcripts, exhibits a highly restricted pattern of expression in a
range of undifferentiated mouse pluripotent cells, including iPSCs.
Regulation of Expression and Mode of Action of Zscan4
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In further analyses we examined whether there was any
correlation between Zscan4 protein expression and the master
regulator, Nanog, known to exhibit fluctuations in expression [46].
Using an ESC line expressing GFP under the control of the
endogenous Nanog promoter (Nanog-GFP; [46]) no clear
correlation between Zscan4 expression and levels of Nanog was
observed (Figure 2C).
Zscan4 gene expression is regulated by the p110a
isoform of phosphoinositide-3 kinases
We originally identified Zscan4c as a gene that was rapidly
down-regulated upon inhibition of PI3K signaling in mouse ESCs
[24]. In this earlier study we had used the broad selectively PI3K
inhibitor, LY294002, which targets most PI3K isoforms. Owing to
the significant interest in the PI3K signaling pathway as a drug
target, small molecule inhibitors, which show selectivity for specific
PI3K isoforms, have become available [47]. Mouse ESCs express
three of the class 1 PI3K catalytic isoforms, p110a, p110b and
p110d [48]. Therefore, we investigated the coupling of specific
p110 PI3K catalytic subunit isoforms to regulation of Zscan4
expression, initially using qRT-PCR. As shown in Figure 3A,
inhibition with LY294002 led to a reduction of approximately
80% in Zscan4 transcripts, consistent with previous results [24].
Inhibition of p110b isoform with either TGX121 (Fig. 3A(i)) or
TGX221 (Fig. 3A(ii)) or inhibition of the p110d isoform with
IC87114 (Fig. 3A(i)) did not alter Zscan4 RNA levels. In contrast,
inhibition of p110a with PIK75 (Fig. 3A (ii)), which is among the
most selective p110a inhibitors available to date [49], led to a
reduction in Zscan4 expression to the same extent to that observed
with LY294002. An un-related p110a inhibitor, compound 15e,
also led to a reduction in Zscan4 expression, while the mTOR
inhibitor, Rapamycin, had no effect (Supplemental Figure S6).
Treatment with LY294002 or PIK-75 also resulted in a significant
(3–4-fold) reduction in the number of Zscan4 positive cells present
within the treated population (Fig. 3B) and these data were further
confirmed by immunoblot analyses (data not shown). To further
investigate the regulation of Zscan4 expression by the p110a PI3K
isoform, we over-expressed a myristyolated version of p110a (myr-
p110a) under the control of the CAG promoter [50] in OCRG9
mESCs. Zscan4 expression was analysed by qRT-PCR in three
independent clones over-expressing myr-p110a. Consistent with
our loss of function data, expression of p110a led to a significant
up-regulation in Zscan4 expression (Figure 3D) and this was
observed in cells grown with or without LIF for 4 days.
Involvement of Gsk-3-dependent signaling in regulation
of Zscan4 expression
We next investigated whether other pathways implicated in the
coordination of ESC self-renewal and pluripotency also control
Zscan4 expression. Inhibition of Gsk-3 has been implicated in the
maintenance of ESC self-renewal [8,9], as well as the ground state
of ESC pluripotency [10] and our previous work has demonstrated
that short-term treatment with the Gsk-3 inhibitor BIO leads to a
small, but significant increase in Zscan4 RNA expression [24].
Here we investigated Zscan4 expression in ESCs in which all 4
Gsk-3 alleles have been knocked out (DKO; [37]) compared to
their wild-type parental cells incubated with or without the more
selective Gsk-3 inhibitor, 1 m [8]. Interestingly, levels of Zscan4
protein were much higher in Gsk-3 double knock-out ESCs, both
in the presence and absence of LIF (Fig. 4A and C), when
compared to WT ESCs, while treatment of WT ESCs with 1 m
for 24 or 48 h had little influence on Zscan4 expression (see Fig. 4A
and B). These data suggest long-term inactivation of Gsk-3 leads to
Figure 1. Expression patterns of Zscan4 gene paralogues in
mouse ESC lines. A. The mouse ESC lines E14 or CCE were cultured in
the presence of KO serum replacement and LIF, RNA was extracted,
limited amplification by RT-PCR was performed and fragments cloned.
96 independent clones were sequenced and categorised as represent-
ing one of the 9 mouse Zscan4 paralogues present in the NCBIm37
database based on SNPs. The relative expression of each Zscan4
paralogue, as a percentage of the total number of Zscan4 gene
sequences obtained for E14 and CCE ESCs, are shown in comparison
with the 129.3 ESC line, data derived from that presented in [26]. B. The
suggested evolution of Zscan4 genes in the mouse based on sequence
variation. Dendrogram (Unweighted Pair-Groups Method using Aver-
ages) showing genetic relationship between Zscan4 paralogs based on
Nei’s [1972] original distance with 1000 bootstrap replications
(confidence values given at each node). The dendrogram was produced
using Tools for population genetic analysis (www.marksgeneticsof
tware.net).
doi:10.1371/journal.pone.0089821.g001
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Figure 2. Zscan4 protein expression is highly restricted in mouse ESC and iPSC lines. A. The ZE3-MC1 Zscan4 reporter line [25] was
cultured in serum replacement plus LIF, cells were fixed and immunostaining was carried out with pan-Zscan4 antibodies (Red). Expression of the
Emerald reporter is shown (Green) and cells were counterstained with DAPI (Blue). (i) Scale bars = 100 mm. (ii) Scale bars = 5 mm. B. The mouse ESC
and iPSC lines indicated were cultured in the presence of serum replacement plus LIF and subsequently fixed and immunostained with the pan-
Zscan4 antibody, while nuclei were counter-stained with DAPI. The proportion of Zscan4 positive cells present were determined by counting several
thousand cells for each cell line sample. Data represent average of three independent replicates 6 SEM, unless otherwise indicated. C. A colony of
Nanog-GFP reporter cells stained with the anti-Zscan4 antibody. (i) The GFP reporter (Green), Zscan4 (Red) and nuclei (DAPI, Blue) are shown, along
with a merged image. (ii) Nanog-GFP cells were stained for Zscan4 protein. The levels of Nanog-GFP and Zscan4 protein expression were calculated
using Cell-P (Olympus) using fluorescent images captured using an Olympus IX51 epifluorescence microscope. Mean fluorescence intensity for GFP
(Nanog) was compared between all cells, Zscan4 expressing (+ve) and non-expressing (2ve) cells.
doi:10.1371/journal.pone.0089821.g002
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up-regulation of Zscan4 expression and consistent with this we
find that culture of WT ESCs in 1 m for 14 days leads to a
corresponding increase in Zscan4 RNA expression (data not
shown). Having established that long-term inhibition of Gsk-3
results in enhanced levels of Zscan4 protein we wondered whether
Gsk-3 plays a role in regulating the stability of Zscan4 protein, as it
does for other regulators of pluripotency, including ß-catenin and
c-Myc. To assess protein half-life, WT ESCs incubated with or
without 1 m (Gsk-3 inhibitor) (Figure 4B) or DKO (Figure 4C)
ESCs were treated with cycloheximide for 1 to 6 h. These data
suggest that Zscan4 protein has a half-life of between 3–6 h, which
is not notably prolonged upon disruption of Gsk-3 activity.
Zscan4 expression is induced in response to DNA
damage
Zalzman et. al., [25] reported that Zscan4 is key to maintaining
the genomic integrity of mouse ESCs. We predicted that if this
were the case, then Zscan4 expression may be sensitive to the
effects of DNA damage-inducing agents, so we examined whether
Zeocin, which induces double strand breaks, or Cisplatin, an
alkylating-like agent that induces DNA cross-links leading to
double strand breaks via stalled replication forks, affect expression
of Zscan4. As shown in Fig. 5A, a 12 h treatment with Zeocin
followed by wash-out and incubation for a further 8 and 24 h led
to a dose-dependent increase in Zscan4 expression (Fig. 5A (i) and
(ii)). In the case of Cisplatin treatment (12 h), a notable
enhancement of Zscan4 expression was detected 24 h following
wash-out (Figure 5B (i) and (ii)). Induction of cH2AX and the
proportion of cells in G2/M phase of the cell cycle were measured
to assess the cellular response to these agents (Fig. 5 A and B,
panels (i) and (iii)), which showed enhanced cH2AX phosphory-
lation and accumulation of cells in G2/M phase. Not only were
levels of Zscan4 protein enhanced following exposure to Zeocin,
but treatment with Zeocin also led to an increase in the proportion
of ESCs expressing detectable Zscan4 protein (Fig. 5C(i)), a
response partly attenuated by the PI3K inhibitor LY294002
(Fig. 5C(ii)). While the absolute frequency of Zscan4 positive cells
varied, due to variation in levels in control populations, we
consistently observed a 4–10-fold increase in Zscan4 positive cells
following exposure to Zeocin. Phosphorylation of the histone
H2AX (to generate cH2AX) is an indicator of DNA damage-
induced DNA double strand break and basal levels are known to
be elevated in mouse ESCs [51]. However, cH2AX levels are
further elevated in ESCs in response DNA damage (see Fig. 5A(i)
and B(i)), so we examined the relationship between Zscan4
expression and levels of cH2AX. We found levels of cH2AX were
higher in Zscan4 positive cells both under basal (control)
conditions and also following treatment with Zeocin (Fig. 5D),
consistent with DNA damage corresponding to enhanced Zscan4
expression.
Figure 3. Zscan4 gene expression is regulated by the p110a
isoform of PI3Ks. A. (i) and (ii) E14 ESCs were cultured in the
presence of LIF, with the addition of DMSO (control) or the inhibitors
indicated: 5 mM LY294002 (broad spectrum PI3K inhibitor), 10 mM
TGX121 (p110b), 5 mM IC87114 (p110d), 25 nM PIK75 (p110a), 100 nM
TGX221 (p110b), for 48 h. RNA was extracted and levels of Zscan4
expression analysed by qRT-PCR and normalised to levels of b-actin.
Mean values are shown with standard deviations (n = 4). **, p,0.005,
***, p,0.0005 in a Student’s t-test. B. ESCs were cultured in LIF and
treated with either DMSO as a control or with 5 mM LY294002 (LY),
10 nM PIK75, 50 nM TGX221 (TGX), or 5 mM IC87114 for 48 h prior to
immunostaining for Zscan4. The mean percentage of Zscan4 positive
cells with SEM are shown. *, p,0.05, **, p,0.005 following an ANOVA
and Tukey’s post-hoc test. C. ESC clones over-expressing myristoylated
p110a catalytic subunit of PI3Ks were cultured in the presence or
absence of LIF. As a control parental OCRG9 ESCs were grown in
presence and absence of LIF for 4 days. Expression of Zscan4 was
analysed by qRT-PCR and Zscan4 expression normalised to levels of
GAPDH. The averages and SEM of triplicate samples from each of three
independent biological replicates are shown: ***, p,0.0005, in a
Student’s t-test.
doi:10.1371/journal.pone.0089821.g003
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Zscan4 expression is elevated in late S-phase/early G2 of
the cell cycle
During our analyses of Zscan4 protein expression by immuno-
staining we noted that positive cells often appeared in close
proximity to each other (see Figure 2). Enumerating the
proportion of Zscan4 positive cells appearing as single cells,
doublets, triplets or quadruplicates (shown in Figure 6A(i)),
revealed that approximately 45% of Zscan4 positive cells occur
in close proximity to at least one other Zscan4 positive cell. This
prompted us to investigate whether Zscan4 proteins were
expressed preferentially by cells just prior to or during mitosis.
Using the ZE3-MC1 reporter line we investigated the cell cycle
distribution profiles of Zscan4 positive and negative cells. As
shown in Figure 6A(ii), of all Zscan4 positive cells, approximately
45% were in G2/M phase of the cell cycle, very consistent with
our proximity data. Furthermore, the mean fluorescence intensity
of Emerald-GFP was highest in cells in G2/M (Figure 6A(iii)),
consistent with Zscan4 expression being elevated in cells during
these cell cycle phases. To examine this correlation further, we
induced mitotic arrest of ESCs using Nocodazole and after release
followed both progression through the cell cycle and expression of
Zscan4 protein. As shown in Figure 6B(i–iii) approximately 90% of
cells were arrested in G2/M by Nocodazole treatment (100 ng/
ml). 3 h after release many cells had re-entered G1 (Fig. 6B(ii)),
after 6–9 h cells had started to transit through S-phase (Fig. 6B(iii))
and by 12 h were entering G2/M, all consistent with the reported
pattern of the ESC cell cycle [52]. Interestingly, Nocodazole
treatment alone did not lead to an increase in Zscan4 expression
and instead Zscan4 protein levels remained at a constant level
until 12 h, when they rose by approximately 4-fold, with the rise
continuing to 18 h (Figure 6B(iv)). These data indicate that Zscan4
expression increases as cells transit from late S-phase and into G2
and implicate a selective role for Zscan4 during the G2
checkpoint.
Zscan4 can modulate transcription and interacts with co-
repressor complexes in undifferentiated ESCs
To understand the mechanism of action of Zscan4 in regulation
of ESC fate, particularly how this may relate to a specific role
during G2, we investigated the ability of Zscan4 to act as a
regulator of transcription. Other Scan-domain and zinc finger
containing proteins have been shown to act as transcriptional
Figure 4. Long-term inhibition of Gsk-3 signalling leads to up-regulation of Zscan4 protein expression. A. Wild-type (WT) and Gsk-3
double knock-out (DKO) ESCs cells were grown in the presence or absence of LIF for the times indicated. WT ESCs cultured in the absence of LIF were
also incubated with 2 mM 1 m. Protein and RNA were extracted at the times indicated and immunoblotting performed with the indicated antibodies.
B. WT mESCs (CTL) cultured for 24 h in N2B27 plus LIF and BMP4 with or without 2 mM 1 m, or C. WT or DKO ESCs cultured in N2B27 plus LIF and
BMP4, were incubated with Cycloheximide (CHX) to halt protein synthesis. (i) Protein samples were extracted after 0, 1, 3 and 6 hours CHX treatment
and immunoblotting performed with the indicated anti-Zscan4 or GAPDH antibodies. (ii) Zscan4 protein levels were normalised to GAPDH and a
value of 100 was given to the t = 0 samples, to allow direct comparison of half-life values between treatments. The graphs show the average and
S.E.M of triplicate experiments.
doi:10.1371/journal.pone.0089821.g004
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regulators [53] and while over-expression of Zscan4 has been
shown to lead to changes in expression of ,1000 genes [54], there
is no evidence that it acts directly. To examine the ability of
Zscan4 to act as a regulator of transcription, we used the GAL4-
UAS-luciferase reporter system and generated a series of GAL4-
DNA binding domain-Zscan4c fusions, depicted in Fig. 7A. As a
control for this assay, we also generated a GAL4-DBD-Nanog
fusion. Transient transfection into heterologous HEK293 cells was
performed with combinations of the GAL4-UAS-luciferase
reporter (containing a synthetic GAL4-UAS promoter, see
supplemental Figure S3), GAL4-DBD fusions and Renilla plasmid
to control for transfection efficiency. As shown in Fig. 7B,
compared to the GAL-DBD alone, fusion of the GAL-DBD with
Nanog, the Zscan4c Scan domain alone or full-length Zscan4c,
lead to significant decreases in luciferase activity, consistent with
transcriptional repression. These data are consistent with Zscan4c
playing a direct role in regulating transcription and led us to
undertake studies to define Zscan4-interacting proteins in the
nucleus of ESCs, which could assist in further definition of the
mode of action of Zscan4.
To facilitate purification of Zscan4c interacting proteins, we
constructed an eGFP-Zscan4c fusion protein, expressed in R1
ESCs under the control of the pTRE-tight, Dox-inducible
expression system (Supplemental Figure S1). Following induction
of eGFP-Zscan4c for 24 h, cytosolic and nuclear extracts were
prepared and affinity purification performed with GFP-TrapA
beads. Induced and un-induced extracts were subjected to the
same procedure and after affinity purification and extensive
washing protein complexes were released and separated by SDS-
PAGE. After staining with Coomassie Blue, protein bands of
approximately 116, 100, 75 and 50 kDa, were consistently
enriched in the material affinity purified from the induced
samples. These proteins were excised and submitted for sequenc-
ing at the University of Bristol Proteomics Facility. Following
proteolytic digestions with trypsin, tandem mass spectrometry was
used to generate peptide mass fingerprints and the Mascot search
engine (Matrix Science) exploited to identify proteins. Following
these analyses, the 116 kDa protein was identified as the lysine
specific demethylase, LSD1, the 100 kDa and 75 kDa proteins as
full-length and truncated versions of eGFP-Zscan4c fusion protein
respectively and the 50 kDa protein as the transcriptional co-
repressor, C-Terminal Binding Protein-2 (CtBP2).
To confirm these Zscan4 protein-protein interactions we first
assessed interaction of Zscan4c with LSD-1 and CtBP2 in the
eGFP-Zscan4c fusion expressing ESCs. As shown in Figure 7C,
the GFP-TrapA beads precipitate the GFP-Zscan4c fusion protein
and co-precipitate both LSD-1 and CtBP2 in samples prepared
following Dox-induction of eGFP-Zscan4c expression. Further-
more, following immunoprecipitation of LSD-1, eGFP-Zscan4c
can be detected in Dox-induced samples. CtBP2 has been reported
to form complexes with LSD-1 and we confirm this in mESCs, as
CtBP2 is also present in LSD-1 precipitates. We also examined co-
precipitation with a version of Zscan4c containing a C-terminal
V5 epitope tag. Expression of Zscan4c-V5 is under the control of
the Tet-off expression system and as shown in Figure 7D, probing
LSD-1 and CtBP2 immunoprecipitates with either anti-V5 epitope
or anti-pan Zscan4 antibodies, demonstrates the presence of
Zscan4 in those precipitates prepared following Tet-removal,
which induces Zscan4c-V5 expression. Interestingly, the Zscan4-
V5 precipitating with LSD-1 migrates more slowly than that co-
precipitating with CtBP2, suggesting that Zscan4 may be
participating in distinct protein complexes and subjected to post-
translational modification. This is also apparent when LSD-1 and
CtBP2 precipitates are probed with the pan-Zscan4 antibody
(Fig. 7D, lower panel) and in these samples there is also evidence
for precipitation of endogenous Zscan4 in the +Tet samples which
do not over-express Zscan4c-V5. Next we attempted to confirm
these interactions in wild-type ESCs, expressing endogenous levels
of Zscan4 proteins, a considerable challenge based on our
demonstration that less than 1% of the ESC population are
expressing Zscan4. As shown in Figure 7E, Zscan4 can be detected
in both LSD-1 and CtBP2 precipitates prepared from WT E14
ESCs. Again, LSD-1-associated Zscan4 exhibited slower migration
compared to that associated with CtBP2. It has been suggested
that the SCAN domain mediates dimerisation [27,28,29]. To
examine whether this is the case for Zscan4, we precipitated with
anti-V5 epitope antibodies and examined if endogenous Zscan4
protein could be co-precipitated. Figure 7F shows that endogenous
Zscan4 is present in anti-V5 precipitates, suggesting that
exogenously expressed Zscan4c can form dimers with endogenous
Zscan4 proteins. Taken together, using three different cell lines,
these results confirm that Zscan4 proteins are able to form
complexes with LSD-1 and CtBP2 and potentially exist as dimers
within ESCs, providing important new insights into the mode of
action of Zscan4.
Discussion
The Zscan4 family of genes have been implicated in the control
of early development [26], ESC pluripotency [24] and genome
stability/integrity [25], but their regulation and mode of action
remain enigmatic. Here we demonstrate that Zscan4c, 4f and ps2
are the most abundant and consistently expressed members of this
family, but despite this, expression of Zscan4 protein is restricted
to between only 0.1 and 0.7% of ESCs. Significantly, Zscan4
expression was found to be highest in cells transiting late S-phase/
early G2 of the cell cycle and we show that DNA damage-inducing
agents lead to enhancement of Zscan4 expression, corresponding
with accumulation of cells in G2/M. Together these data suggest
that Zscan4 plays a selective role in ESCs during G2. Our
demonstration that Zscan4 can directly regulate transcription and
exists in complexes with LSD-1 and CtBP2 sheds new and
important light on its mode of action. These findings lead us to
suggest that the Zscan4 family of genes represents an intriguing
paradigm for factors that regulate the ESC state.
Figure 5. Zscan4 expression is enhanced in response to DNA damage induction. E14 ESCs were plated in the presence of LIF for 4 h prior
to application of A. Zeocin or B. Cisplatin for 12 h. After this cells were washed extensively and fresh media added. Following a further 8 or 24 h
samples were taken and cells fixed for cell cycle analysis or protein extracted into RIPA buffer. (i) Levels of H2AX phosphorylation at S139 (cH2AX) and
Zscan4 protein expression were examined by immunoblotting. (ii) Zscan4 protein expression normalized to GAPDH is shown. (iii) The percentage of
cells in G2/M phase of the cell cycle are shown for different samples. C. (i) The percentage of Zscan4 positive cells were determined after 24 h
treatment with the indicated doses of Zeocin. (ii) The effect of inhibition of PI3Ks by LY294002 (LY, 5 mM) on the ability of Zeocin to induce Zscan4
expression was examined following 24 h treatment (12.5 mg/ml). In each case the mean and SEM are shown. *, p,0.05, **, p,0.005, ***, p,0.0005
following an ANOVA and Tukey’s post-hoc test. D. (i) E14 ESCs were co-stained for cH2AX and Zscan4 and the mean fluorescence intensity of cH2AX
staining determined for Zscan4 positive and negative populations using Cell-P (Olympus). ***, p,0.0005, in a Student’s t-test. Representative images
are shown in (ii).
doi:10.1371/journal.pone.0089821.g005
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The very restricted pattern of expression reported for the
Zscan4 family is highly distinctive [25,26], although one caveat to
these previous reports has been that they only measured RNA or
reporter levels. Our data indicate that the proportion of ESCs
within a population expressing Zscan4 protein is between 0.1 and
0.7%, 10-fold lower than the 5% previously reported [25].
Interestingly, we found this level of expression to be consistent
across a number of mouse ESC lines and also observed with an
iPSC line. We do not think the difference in the proportion of
Zscan4 positive cells detected in our study versus previous studies
Figure 6. Zscan4 expression is enhanced in late S/early G2 phase of the cell cycle. A. (i) The proportion of Zscan4 positive cells appearing
as individual single cells or in proximity with one, two or three other Zscan4 positive cells were determined. Mean and SEM are shown. Average
frequency of Zscan4 positive cells was 0.4%. (ii) ZE3-MC1 ESCs were grown in the presence of LIF for 48 h, trypsinised and Nuclear-ID Red (Enzo) used
to stain cellular DNA. Cells were analysed by flow cytometry and G1, S and G2/M gates were assigned to the population based on DNA content and
using a Nocodazole treated sample as a reference. The cell cycle distribution of GFP negative and positive populations are presented, the mean and
SEM are shown (n= 3). *, p,0.05, **, p,0.005, ***, p,0.0005, in a Student’s t-test. (iii) The mean fluorescence intensity of the GFP positive (Zscan4c
expressing) cells distributed in the different cell cycle phases. In each case the mean and SEM are shown. *, p,0.05, **, p,0.005, ***, p,0.0005
following an ANOVA and Tukey’s post-hoc test. B. E14 ESCs were cultured in LIF and treated with 100 ng/ml Nocodazole for 12 h to induce mitotic
arrest. Following release from the block, cell cycle analyses ((i), (ii) and (iii)) and immunoblotting, to detect Zscan4 protein expression (iv) were
performed at the times indicated (n = 3). Mean and SEM are shown on the graphs. Zscan4 protein expression was normalised to GAPDH ((iv), lower
panel).
doi:10.1371/journal.pone.0089821.g006
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Figure 7. Zscan4 acts as a transcriptional regulator and interacts with LSD-1 and CtBP2. A. Schematic showing the structure of GAL4-DNA
binding domain fusions with Zscan4c. B. Plasmids expressing the GAL-4-DNA binding domain fusions indicated were co-transfected into HEK293
cells along with pGL4-GAL4-UAS plasmid and the pRenilla plasmid (to assess transfection efficiency). 48 h after transfection luciferase activity was
determined using Dual-Glo system, according to the manufacturer’s recommendations (Promega). Mean and SEM of 3 independent experiments are
shown. *, p,0.05, **, p,0.005 following an ANOVA and Tukey’s post-hoc test. C. ESCs engineered to express an N-Terminal eGFP-Zscan4c fusion
protein under the control of the pTRE tight Dox-inducible expression system were cultured in the absence (2) or presence (+) of Dox for 72 h.
Nuclear extracts were prepared (Nuc) and immunoprecipitates prepared from 80 mg of protein per sample using either GFP-Trap-A beads or anti-LSD-
1 antibodies. Precipitates were divided into two aliquots and separated through 10% polyacrylamide on duplicate gels, prior to immunoblotting.
Immunoblotting was performed with anti-GFP, anti-CtBP2 or anti-Zscan4 antibodies, sequentially with one immunoblot. The duplicate immunoblot
was probed with anti-LSD-1 antibodies. Positions of precipitated proteins are indicated. D. ESCs engineered to express a C-Terminally V5 epitope-
tagged version of Zscan4c under the control of the Tet-off expression system were cultured in the presence (+) or absence (2) of Tet for 72 h. Nuclear
extracts were made (Nuc) and immunoprecipitates prepared from 80 mg of protein per sample using either anti-LSD-1 or anti-CtBP2 antibodies or
protein-A sepharose (PAS) alone as a control. Precipitates were separated through 7.5% polyacrylamide gels prior to immunoblotting.
Immunoblotting was first performed with anti-Zscan4 antibodies. The blots were then stripped and reprobed with anti-V5 epitope antibodies.
Positions of precipitated proteins are indicated. E. Nuclear extracts (Nuc) were prepared from E14 ESCs and precipitates from 200 mg of protein per
sample generated using anti-Zscan4, anti-LSD-1 or anti-CtBP2 antibodies. Precipitates were separated through a 6.5% polyacrylamide gel prior to
immunoblotting and the lanes between the samples were left blank to avoid the potential of any bleed-through. Immunoblotting was performed
with anti-Zscan4 antibodies. Positions of precipitated proteins are indicated. F. ESCs engineered to express a C-Terminally V5 epitope-tagged version
of Zscan4c under the control of the Tet-off expression system were cultured in the presence (+) or absence (2) of Tet for 72 h. Nuclear extracts were
prepared (Nuc) and immunoprecipitates prepared from 80 mg of protein per sample using anti-V5 epitope antibodies. Precipitates were separated
through a 7.5% polyacrylamide gel prior to immunoblotting. Immunoblotting was performed with anti-Zscan4 antibodies. Positions of precipitated
proteins are indicated.
doi:10.1371/journal.pone.0089821.g007
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is due to post-transcriptional regulation, since we saw a robust
correlation between reporter expression in the ZE3-MC1 line and
detection of Zscan4 protein. In addition, this is the same reporter
line used by the Ko group [25] but we record fewer Zscan4
positive cells than previously reported. In view of this, it may be
that Zscan4 expression is influenced by variation in culture
conditions, although when we evaluated this no clear factors
emerged. Alternatively, we may have set more stringent thresholds
for detection of Zscan4 protein expression, which would have
decreased the number of positive cells scored. Nevertheless, it is
clear from previous work and the new data that we report here
that Zscan4 is expressed by only a small proportion of ESCs in
culture. Such a restricted pattern of expression is quite unprec-
edented in the ESC field and leads to the question of how Zscan4
expression is regulated. Of relevance here is a recent study that has
reported the identification of a rare and transient population of
cells within ESC cultures that share properties and expression
profiles with two-cell stage embryos [55]. This is interesting from
the point of view of the Zscan4 family, since Zscan4d was first
identified as a gene whose expression was elevated during zygotic
genome activation and highly expressed in 2-cell stage embryos
[26]. Macfarlan et al., report that many of the ‘2C’ transcripts
detected in this transient sub-population of ESCs are initiated
from the LTRs of endogenous retroviruses, including those of
Zscan4 [55]. Thus, it is possible that activation of these
endogenous retroviral elements play a role in establishing the
highly restricted pattern of expression of Zscan4 proteins within
ESC populations. Furthermore, it is tempting to speculate that
Zscan4 is a marker of this rare and transient ‘2C’ stem cell
population and given that RNAi knock-down of Zscan4 leads to
arrest of 2-cell embryo development [26], it could play an
important functional role in this rare cell population. However,
alternative explanations for the restricted pattern of expression of
Zscan4 also need to be considered and explored, including auto-
regulatory or oscillatory-based mechanisms. Further work will be
required to distinguish between these possibilities.
Based on the evidence published to date [24,25,26,33,35,55], it
seems likely that Zscan4 plays multiple roles in pluripotent cells
and we were particularly interested to discover that Zscan4
expression varied at different stages of the cell cycle. Initially our
observation that 45% of Zscan4 positive cells were found in close
proximity to another Zscan4 positive cell led us to consider that
Zscan4 expression may be enriched in cells undergoing mitosis.
However, when ESCs were treated with Nocodazole, which leads
to arrest in pro-metaphase, Zscan4 expression was not elevated.
Instead, upon release and progression through the cell cycle,
increases in Zscan4 protein levels corresponded with the stage at
which cells transited late S-phase and entered early G2. Further
support for a role of Zscan4 in G2 phase of the cell cycle comes
from our studies examining regulation of Zscan4 expression in
response to DNA damaging agents. Both Zeocin and Cisplatin
induce double-stranded DNA breaks, as measured by an increase
in cH2AX, which lead to cell cycle arrest in G2/M [56]. We
detected the highest levels of Zscan4 induction by Zeocin at the
point when the number of cells in G2/M had increased from 40 to
65%. In the case of Cisplatin, the most significant elevation in
Zscan4 expression was observed with the highest dose of Cisplatin
we used following a 24 h recovery phase. At this same time point,
the proportion of cells in G2/M had increased from 40 to 57%.
While we had initially assessed cell cycle profiles of these cells to
gauge the ESC response to DNA damage-inducing agents, these
data provide additional evidence to support the fact that Zscan4
expression is preferentially increased during G2-phase of the cell
cycle. Furthermore, it is worth noting that temporal changes in
Zscan4 expression do not follow the profile of cH2AX detection,
indicating Zscan4 up-regulation is not an early response to DNA
damage. Given the report that Zscan4 plays a critical role in
telomere elongation and genome integrity in mouse ESCs [25] our
demonstration that agents that damage DNA lead to an
enhancement in Zscan4 expression is consistent with a role for
Zscan4 in genome surveillance and maintenance.
The fact that members of the Zscan4 family contain zinc finger
domains has led to the suggestion that they act as transcription
factors [24], as do other members of the SCAN-domain
containing family [53]. Over-expression of Zscan4 in mouse ESCs
has been reported to result in the change in expression of over
1000 genes [54], while inclusion of Zscan4 as a reprogramming
factor for mouse embryo fibroblasts results in the transient
induction of pre-implantation specific genes [33]. Despite these
reports, evidence to support the ability of Zscan4 to directly
regulate transcription has been lacking. Using a heterologous
reporter system, we demonstrate that Zscan4 can act as a
transcriptional regulator. Both full-length Zscan4 and the SCAN
domain alone were able to repress GAL4 binding domain-
mediated reporter expression (Figure 7B). This could be due to the
ability of the SCAN domain to promote dimerisation, as
demonstrated for other SCAN-domain-containing proteins
[28,29]. Importantly, we provide the first evidence that Zscan4
may act as a dimer, since we show that a V5-epitope-tagged
version of Zscan4 co-precipiates endogenous Zscan4 proteins
(Figure 7F). To gain further insight into the mode of action of
Zscan4, we investigated whether Zscan4 interacted with other
proteins within ESC nuclei. Our analyses revealed two major
interacting proteins -LSD-1 and CtBP2. LSD1 has been reported
to specifically demethylate mono and di-methyl histone H3 at K4
and K9 and thus acts as a co-repressor of transcription. CtBP2
belongs to a class of transcriptional co-repressors that bind to
transcription factors via a PXDLS motif and has been shown to
interact with a range of Zinc finger containing transcriptional
regulators [57,58]. Zscan4c exhibits a PXDLS motif at position
263–268, as do Zscan4 family members, suggesting that each of
them can bind CtBP2. Importantly, both LSD-1 and CtBP2 have
been reported to be components of the CoREST-CtBP repressor
complex [58,59]. Thus, the identification of these two proteins as
Zscan4c interacting partners in ESCs is consistent with the fact
that Zscan4c is a putative regulator of transcription, possibly
involved in repression of transcription. It has been suggested that
the fact Zscan4 over-expression leads to minor changes in the
transcriptome during early reprogramming events, but major
differences in iPSC outcome, indicates it acts differently to many
other factors and may be involved in epigenetic regulation or
chromatin remodeling [33]. Our finding that Zscan4 interacts
with LSD-1 is consistent with this latter possibility. In future
studies it will be interesting to determine the genes that are directly
targeted by Zscan4 in ESC and iPSCs and compare these to
known targets of LSD-1 and CtBP2.
Our expression data indicate that three Zscan4 genes are most
abundantly expressed in ESCs, namely Zscan4c, 4f and ps2.
Zscan4-ps2 has previously been characterized as a pseudogene,
primarily based on the fact that in a previous study no ps2
transcripts were detected in mouse ESCs [26], although in contrast
our data indicate Zscan4-ps2 transcripts can be detected in mouse
ESCs. Given the close relationship between Zscan4c, 4f and ps2
(Fig. 1B), it is intriguing that these should consistently be the most
highly expressed in different ESCs lines, but argues for a
predominant role of their gene products. Also worth noting is
the fact that the p110a isoform of PI3Ks plays the predominant
role in regulating Zscan4 expression, supported by both loss and
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gain of function studies (Figure 3). We have previously implicated
p110a PI3K in regulation of ESC proliferation [48,60], which
complements with the findings we report here relating to Zscan4
expression and the cell cycle. PI3K signaling is one of the
pathways that regulate activity of Gsk-3. Surprisingly, given its role
in the ground state of ESC pluripotency, short-term inhibition of
Gsk-3-dependent signaling did not lead to increased Zscan4
protein expression, whereas a sustained lack of Gsk-3 activity did.
However, no significant increase in the proportion of Zscan4
positive cells was detected in Gsk-3 double knock-out ESCs (data
not shown).
Based on previously published studies and the results we present
here, we would like to suggest that the Zscan4 family represents an
intriguing paradigm for regulators of the for ESC state. Multiple,
closely related Zscan4 genes are co-expressed by ESCs, but despite
this Zscan4 protein is detected in less than 1% of ESCs. Zscan4
expression is higher in cells in late S/early G2-phase of the cell
cycle, consistent with it playing a role during the G2 checkpoint
and genome stability. Related to this we have demonstrated that
Zscan4 acts as a regulator of transcription and interacts with LSD-
1 and CtBP2, suggesting it may have a role in transcriptional
repression. While many questions remain to be answered about
this enigmatic family of zinc finger proteins, our study provides
new and important insight into the regulation and action of
Zscan4 proteins.
Supporting Information
Figure S1 Establishment and characterisation of eGFP-
Zscan4c-Tet-on inducible ESC lines. A. Schematic of the
GFP-Zscan4c fusion protein generated. B. Following induction
with 1 mg/ml doxycycline for the times indicated (in hours, h),
nuclear lysates were prepared from eGFP-Zscan4c ESCs and
immunoblotted with an anti-GFP antibody. Blots were stripped
and re-probed with an anti-TBP antibody to assess the equality of
protein loading. C. Quantitative RT-PCR was used to confirm
induction of Zscan4c expression normalised to b-actin levels. D.
Fluorescent images showing expression of eGFP-Zscan4c (green)
after addition of doxycycline for the times indicated.
(TIF)
Figure S2 Establishment and characterisation of
Zscan4c-V5-His Tet-off inducible ESC lines. A. Immuno-
blots showing induction of Zscan4c-V5-His protein (clone 43)
upon withdrawal of tetracycline (tet) detected with anti-V5
antibody. (i) Expression 24 h after induction in the presence of
different concentrations of LIF (indicated in U/ml). (ii) Expression
of Zscan4c-V5-His was maintained over a time-course of 120 h.
Immunoblots were stripped and re-probed with Oct-4 antibody.
B. (i) Localisation of Zscan4c-V5-His protein was assessed by
immunostaining of Tet-off inducible cell lines grown in the
absence of tetracycline. Anti-V5 antibody was used to detect
Zscan4c-V5 protein (red). Cell nuclei were counter-stained with
DAPI (blue). (ii) Zscan4c-V5-His-Tet-off inducible mESC (clone
45) were grown in the presence and absence of Tet. Cytosolic and
nuclear proteins were separated and immunoblotting performed
with anti-V5, anti-TBP (predominantly nuclear) and anti-GAPDH
(predominantly cytosolic) antibodies.
(TIF)
Figure S3 The sequence (59-39) of the synthetic GAL4-UAS
promoter used to drive luciferase expression in this study. The
strands were mixed, heated to 95uC and cooled before being
ligated into pGL4.26 (Promega).
(TIF)
Figure S4 Zscan4 antibody specificity. ESCs engineered to
express a C-terminally V5 epitope-tagged version of Zscan4c
under the control of the Tet-off expression system were cultured in
the presence (+) or absence (2) of Tet for 48 h when nuclear (Nuc)
and cytoplasmic (Cyto) protein extracts were prepared. A.
Cytosolic and nuclear extracts were separated by SDS-PAGE
and duplicate blots prepared. A 1:2000 dilution of anti-Zscan4
anti-peptide antibody was incubated with or without 1 mg/ml
blocking peptide for 1 h prior to being used for immunoblotting.
B. Immunoprecipitates were prepared from (i) 1 mg of cytosolic
or (ii) 80 mg of nuclear protein extract per sample using either
protein-A sepharose (PAS) bead alone or together with 2 mg anti-
Zscan4 antibody. Precipitates were separated through 7.5%
polyacrylamide gels prior to immunoblotting. Immunoblotting
was performed with anti-V5 epitope (upper panels) or anti-Zscan4
(lower panels) antibodies. Positions of precipitated proteins are
indicated by the arrows.
(TIF)
Figure S5 Assigning Zscan4 gene transcripts. The
transcript sequence from each Zscan4 gene was obtained from
the NCBI database. These were aligned and distinguished based
on the identification of SNPs – highlighted in black in the
schematic. Sequenced Zscan4 cDNAs derived from E14tg2a or
CCE cell lines (numbers assigned based on position in 96-well tray,
e.g. E11, C07 as shown) were edited and added to this alignment.
Sequences were assigned to a Zscan4 gene based on the
distinguishing SNPs each contained. As an example, the 5 SNPs
used to identify Zscan4a transcripts are shown. Sequence data
were edited and aligned using Sequencher (GeneCodes).
(TIF)
Figure S6 Regulation of Zscan4 by the p110a catalytic
subunit of PI3K. E14tg2a cells were treated with either A. 5 mM
LY294002 or 600 nM Compound 15e or B. 5 mM LY294002,
10 mM TGX-121, 5 mM IC87114 or 1 nM Rapamycin. RNA was
extracted 48 h after inhibitor treatment, quantitative RT-PCR
was performed and Zscan4 expression normalised relative to b-
actin levels. Graphs show standard deviation and are representa-
tive of three experimental repeats.
(TIF)
Table S1 Primer sequences used for quantitative RT-PCR.
(DOCX)
Table S2 Primer sequences used for construction of Gal4-
Zscan4 fusion transcriptional reporters.
(DOCX)
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